US20050131005A1 - 4-azasteroid derivatives as androgen receptor modulators - Google Patents

4-azasteroid derivatives as androgen receptor modulators Download PDF

Info

Publication number
US20050131005A1
US20050131005A1 US10/512,800 US51280004A US2005131005A1 US 20050131005 A1 US20050131005 A1 US 20050131005A1 US 51280004 A US51280004 A US 51280004A US 2005131005 A1 US2005131005 A1 US 2005131005A1
Authority
US
United States
Prior art keywords
methyl
androst
oxo
aza
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/512,800
Other languages
English (en)
Inventor
Jiabing Wang
Carol McVean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/512,800 priority Critical patent/US20050131005A1/en
Publication of US20050131005A1 publication Critical patent/US20050131005A1/en
Priority to US11/504,325 priority patent/US7625919B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom

Definitions

  • the present invention relates to 4-azasteroid derivatives, their synthesis, and their use as androgen receptor modulators. More particularly, the compounds of the present invention are tissue-selective androgen receptor modulators and are thereby useful for the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, such as osteoporosis, periodontal disease, bone fracture, frailty, and sarcopenia.
  • the androgen receptor belongs to the superfamily of steroid/thyroid hormone nuclear receptors, whose other members include the estrogen receptor (ER), the progesterone receptor (PR), the glucocorticoid receptor (GR), and the mineralocorticoid receptor (MR).
  • the AR is expressed in numerous tissues of the body and is the receptor through which the physiological as well as the pathophysiological effects of endogenous androgen ligands, such as testosterone (T) and dihydrotestosterone (DHT), are expressed.
  • the AR is composed of three main functional domains: the ligand binding domain (LBD), the DNA-binding domain, and amino-terminal domain.
  • LBD ligand binding domain
  • a compound that binds to the AR and mimics the effects of an endogenous AR ligand is referred to as an AR agonist, whereas a compound that inhibits the effects of an endogenous AR ligand is termed an AR antagonist.
  • Androgen ligand binding to the AR affords a ligand/receptor complex, which, subsequent to translocation inside the nucleus of the cell, binds to specific regulatory DNA sequences (referred to as androgen response elements or AREs) within the promoter or enhancer regions of the target gene or genes present in the cell's nucleus.
  • AREs specific regulatory DNA sequences
  • cofactors are next recruited which bind to the amino-terminal domain or the LBD of the receptor leading to gene transcription and subsequent translation to produce the protein(s) encoded by that gene or genes.
  • Androgen therapy has been used in the clinic to treat a variety of male disorders, such as reproductive disorders and primary or secondary male hypogonadism.
  • a number of natural or synthetic AR agonists have been clinically investigated for the treatment of musculoskeletal disorders, such as bone disease, hematopoietic disorders, neuromuscular disease, rheumatological disease, wasting disease, and for hormone replacement therapy (HRT), such as female androgen deficiency.
  • AR antagonists such as flutamide and bicalutamide, have been used to treat prostate cancer.
  • estrogen—progestin combinations that incorporated an androgenic progestin (such as norethindrone), rather than medroxyprogesterone acetate, yielded greater improvements in hip BMD.
  • CEE oral conjugated estrogen
  • methyltestosterone combinations were demonstrated to be effective in promoting accrual of bone mass in the spine and hip, while conjugated estrogen therapy alone prevented bone loss
  • a common scenario for androgen deficiency occurs in men with stage D prostate cancer (metastatic) who undergo androgen deprivation therapy (ADT). Endocrine orchiectomy is achieved by long acting GNRH agonists, while androgen receptor blockade is implemented with flutamide, nilutamide, bicalutamide, or RU 58841 (AR antagonists). In response to hormonal deprivation, these men suffered from hot flushes, significant bone loss, weakness, and fatigue. In a recent pilot study of men with stage D prostate cancer, osteopenia (50% vs. 38%) and osteoporosis (38% vs.
  • tissue selective AR antagonists in the prostate that lack antagonistic action in bone and muscle may be useful agents for the treatment of prostate cancer, either alone or as an adjunct to traditional ADT such as with a GnRH agonist/antagonist [See also A. Stoch, et al., J. Clin. Endocrin.
  • Tissue-selective AR antagonists may also have utility in the treatment of polycystic ovarian syndrome in postmenopausal women [see C.A. Eagleson, et al., “Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone,” J. Clin. Endocrinol. Metab., 85: 4047-4052 (2000) and E. Diamanti-Kandarakis, “The Effect of a Pure Antiandrogen Receptor Blocker, Flutamide, on the Lipid Profile in the Polycystic Ovary Syndrome,” Int. J. Endocrinol. Metab., 83: 2699-2705 (1998).
  • Osteoporosis is characterized by bone loss, resulting from an imbalance between bone resorption (destruction) and bone formation, which starts in the fourth decade and continues throughout life at the rate of about 1-4% per year [Eastell, “Treatment of postmenopausal osteoporosis,” New Engi. J. Med., 338: 736 (1998)].
  • Eastell “Treatment of postmenopausal osteoporosis,” New Engi. J. Med., 338: 736 (1998).
  • the increase in spinal BMD attained by bisphosphonate treatment can reach 11% after 7 years of treatment with alendronate.
  • the rate of bone turnover differs from site to site, higher in the trabecular bone of the vertebrae than in the cortex of the long bones, the bone resorption inhibitors are less effective in increasing hip BMD and preventing hip fracture. Therefore, osteoanabolic agents, which increase cortical bone formation and bone mass of long bones by stimulating periosteal bone formation, would address an unmet need in the treatment of osteoporosis especially for patients with high risk of hip fractures.
  • the osteoanabolic agents also complement the bone resorption inhibitors that target the trabecular envelope, leading to a biomechanically favorable bone structure (Schmidt, et al., “Anabolic steroid: Steroid effects on bone in women,” In: J. P. Bilezikian, et al., Ed., Principles of Bone Biology, San Diego: Academic Press, 1996).
  • Tissue-selective AR agonists with diminished deleterious effects on the cardiovascular system and limited virilizing potential may be useful as a monotherapy for the prevention and/or treatment of female osteoporosis.
  • a compound with osteoanabolic properties in bone and muscle but with reduced activity in the prostate and sex accessory tissues may be useful for the prevention and/or treatment of male osteoporosis and osteopenia in men, particularly elderly men.
  • Selective androgen receptor modulators may also be useful to treat certain hematopoietic disorders. It is known that androgens stimulate renal hypertrophy and erythropoietin (EPO) production. Prior to the introduction of recombinant human EPO, androgens were employed to treat anemia caused by chronic renal failure. In addition, androgens at pharmacological doses were found to increase serum EPO levels in anemic patients with non-severe aplastic anemia and myelodysplastic syndromes but not in non-anemic patients. Treatment modalities for anemia will require selective action such as may be provided by selective androgen receptor modulators.
  • EPO erythropoietin
  • selective androgen receptor modulators may also have clinical value as an adjunct to the treatment of obesity.
  • This approach to lowering body fat is supported by published observations that androgen administration reduced subcutaneous and visceral abdominal fat in obese men [J.C. Lovejoy, et al., “Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men,” Int. J. Obesity, 19: 614-624 (1995)]. Therefore, SARMs devoid of androgenic effects on prostate may be beneficial in the treatment of obese men.
  • androgen administration resulted in loss of subcutaneous abdominal fat in obese postmenopausal women [J. C.
  • That androgen receptor agonists may also have therapeutic value against neurodegenerative diseases such as Alzheimer's disease (AD) has also been suggested in the art.
  • AD Alzheimer's disease
  • the ability of androgens to induce neuroprotection through the androgen receptor was reported by J. Hammond, et al., “Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons,” J. Neurochem., 77: 1319-1326 (2001).
  • Gouras et al. have observed that testosterone can reduce neuronal secretion of Alzheimer's ⁇ -amyloid peptides and may therefore be protective in the treatment of AD [( Proc. Nat. Acad. Sci., 97: 1202-1205 (2000)].
  • Non-steroidal compounds having androgen receptor modulating properties were disclosed in U.S. Pat. Nos. 5,688,808; 5,696,130; 6,017,924; 6,093,821; WO 01/16139 (published 8 Mar. 2001); and WO 01/16108 (published 8 Mar. 2001), all assigned to Ligand Pharmaceuticals, and in WO 01/27086, assigned to Kaken Pharm. Co. Additional background for the rationale behind the development of Selective Androgen Receptor Modulators is found in L. Zhi and E. Martinborough in Ann. Rep. Med. Chem. 36: 169-180 (2001). Non-steroidal SARMs were disclosed in J. P.
  • SARM compounds in this invention exhibit tissue selective AR agonism in vivo, i.e. agonism in bone (stimulation of bone formation in a rodent model of osteoporosis) and antagonism in prostate (minimal effects on prostate growth in castrated rodents and antagonism of prostate growth induced by AR agonists).
  • the compounds of the present invention identified as SARMs are useful to treat diseases or conditions caused by androgen deficiency which can be ameliorated by androgen administration.
  • Such compounds are ideal for the treatment of osteoporosis in women and men as a monotherapy or in combination with inhibitors of bone resorption, such as bisphosphonates, estrogens, SERMs, cathepsin K inhibitors, ⁇ v ⁇ 3 integrin receptor antagonists, calcitonin, and proton pump inhibitors. They can also be used with agents that stimulate bone formation, such as parathyroid hormone or analogs thereof.
  • the SARM compounds of the present invention may also be employed for treatment of prostate disease, such as prostate cancer and benign prostatic hyperplasia (BPH).
  • BPH benign prostatic hyperplasia
  • compounds of this invention exhibit minimal effects on skin (acne and facial hair growth) and may be useful for treatment of hirsutism. Additionally, compounds of this invention can stimulate muscle growth and may be useful for treatment of sarcopenia and frailty. They can be employed to reduce subcutaneous and visceral abdominal fat in the treatment of obesity. Moreover, compounds of this invention can exhibit androgen agonism in the central nervous system and may be useful to treat vasomotor symptoms (hot flush) and to increase energy and libido, particularly in postmenopausal women. They may be used as neuroprotective agents in the treatment of Alzheimer's disease.
  • the compounds of the present invention may also be used in the treatment of prostate cancer, either alone or as an adjunct to traditional GnRH agonist/antagonist therapy, for their ability to restore bone, or as a replacement for antiandrogen therapy because of their ability to antagonize androgen in the prostate, and minimize bone depletion in the skeletal system. Further, the compounds of the present invention may be used for their ability to restore bone in the treatment of pancreatic cancer as an adjunct to treatment with antiandrogen, or as monotherapy for their antiandrogenic properties, offering the advantage over traditional antiandrogens of being bone-sparing.
  • compounds of this invention can increase the number of blood cells, such as red blood cells and platelets, and may be useful for the treatment of hematopoietic disorders, such as aplastic anemia.
  • compounds of this invention have minimal effects on lipid metabolism.
  • tissue selective androgen receptor agonism listed above the compounds of this invention are ideal for hormone replacement therapy in hypogonadic (androgen deficient) men.
  • the present invention relates to compounds of structural formula I: or an enantiomer or a pharmaceutically acceptable salt thereof, their uses and phramaceutical composition.
  • SARMs selective androgen receptor agonists
  • the present invention also relates to pharmaceutical compositions comprising the compounds of the present invention and a pharmaceutically acceptable carrier.
  • the present invention also relates to methods for the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration in a mammal in need thereof by administering the compounds and pharmaceutical compositions of the present invention.
  • the present invention also relates to methods for the treatment of osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, FHV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, Alzheimer's disease, premature ovarian failure, and autoimmune disease by administering the compounds and pharmaceutical compositions of the present invention, alone or in combination with a therapeutically effective amount of another agent known to be useful to treat these conditions.
  • the present invention relates to compounds that are useful as androgen receptor agonists, in particular, as selective androgen receptor agonists.
  • Compounds of the present invention are described by structural formula I: or an enantiomer or a pharmaceutically acceptable salt thereof; wherein
  • R 1 is hydrogen or C 1-3 alkyl, unsubstituted or substituted with one to seven fluorine atoms.
  • RI is chosen from hydrogen and methyl.
  • One variant of the compounds of the present invention are those compounds wherein a-b represents CH 2 CH 2. In another variant a-b represents CH ⁇ CH.
  • R 4 is selected from C 1-4 alkyl, such as for example, methyl.
  • R 4 together with the carbon atom to which it is attached form a carbonyl or cyclopropyl group.
  • the group is a cyclopropyl group.
  • R 1 and R 4 together with the atoms to which they are attached form a 5- or 6-membered ring system optionally containing an additional heteroatom selected from O, S, and NC 1-4 alkyl.
  • R 2 is hydrogen
  • R 3 is (CH 2 ) n -aryl.
  • (CH 2 ) n -aryl and n is selected from 0 and 1, and aryl is selected from: phenyl, imidazopyridinyl, benzimidazolyl, benzothiophenyl, indolyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, pyrazolyl, pyrrolyl, pyridyl, pyriridyl, pyrazinyl, thiadiazolyl, triazolyl, and indanyl.
  • R 3 is selected from phenyl, benzimidazolyl, benzothiophenyl, indolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidyl, pyrazinyl, thiadiazolyl, imidazopyridinyl, and triazolyl.
  • R 1 is methyl and R 3 is selected from phenyl, benzimidazolyl, benzothiophenyl, indolyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidyl, pyrazinyl, thiadiazolyl, imidazopyridinyl, and triazolyl.
  • R 4 is selected from C 1-4 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents independently selected from cyano, carboxy, halogen, hydroxy, oxo, C 1-4 alkoxy, and C 1-4 alkylthio, (CH 2 ) n -phenyl, and halogen.
  • R 4 is a methyl group. In another embodiment, R 4 together with the carbon atom to which it is attached form a cyclopropyl group.
  • the compounds of the invention are selected from:
  • the compounds are selected from:
  • the compounds of formula (I) are selected from:
  • the compounds of formula (1) are selected from:
  • the compounds of the present invention are selected from:
  • the compounds of the invention are selected from:
  • the compounds of the invention are selected from:
  • the compounds of formula (1) are selected from:
  • the compounds are selected from:
  • the compounds of formula (1) are selected from:
  • the compounds of the present invention are selected from:
  • Y“alkyl” shall mean straight or branched chain alkanes of one to ten total carbon atoms, or any number within this range (i.e., methyl, ethyl, 1-propyl, 2-propyl, n-butyl, s-butyl, t-butyl, etc.).
  • C 0 alkyl (as in “C 0-8 alkylaryl”) shall refer to the absence of an alkyl group.
  • alkenyl shall mean straight or branched chain alkenes of two to ten total carbon atoms, or any number within this range.
  • alkynyl shall mean straight or branched chain alkynes of two to ten total carbon atoms, or any number within this range.
  • alkylidene shall mean a straight or branched chain alkylidene group of one to ten total carbon atoms, or any number within this range.
  • cycloalkyl shall mean cyclic rings of alkanes of three to eight total carbon atoms, or any number within this range (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl).
  • cycloheteroalkyl shall mean a 3- to 8-membered fully saturated heterocyclic ring containing one or two heteroatoms chosen from N, O, or S.
  • cycloheteroalkyl groups include, but are not limited to, piperidinyl, pyrrolidinyl, azetidinyl, morpholinyl, and piperazinyl.
  • cycloheteroalkyl is selected from piperidinyl, pyrrolidinyl, and morpholinyl.
  • alkoxy refers to straight or branched chain alkoxides of the number of carbon atoms specified (e.g., C 1-5 alkoxy), or any number within this range (i.e., methoxy, ethoxy, etc.).
  • aryl refers to a monocyclic or bicyclic system comprising at least one aromatic ring, wherein the monocylic or bicyclic system contains 0, 1, 2, 3, or 4 heteroatoms chosen from N, O, or S, and wherein the monocylic or bicylic system is either unsubstituted or substituted with one or more groups independently selected from halogen, phenyl, C 1-8 alkyl, C 3-8 cycloalkyl, C 3-8 cycloheteroalkyl, phenyl-C 1-6 alkyl, amino-C 0-6 alkyl, C 1-6 alkylamino-C 0-6 alkyl, (C 1-6 alkyl) 2 amino-C 0-6 alkyl, phenyl-C 0-6 alkylamino-C 0-6 alkyl, (phenyl-C 0-6 alkyl) 2 amino-C 0-6 alkyl, C 1-6 alkylthio, phenyl-
  • the aryl group is unsubstituted, mono-, di-, or tri-substituted with one to three of the above-named substituents; more preferably, the aryl group is unsubstituted, mono- or di-substituted with one to two of the above-named substituents.
  • alkyl or aryl or either of their prefix roots appears in a name of a substituent (e.g., aryl C 0-8 alkyl), it shall be interpreted as including those limitations given above for “alkyl” and “aryl.” Designated numbers of carbon atoms (e.g., C 0-8 ) shall refer independently to the number of carbon atoms in an alkyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
  • arylalkyl and “alkylaryl” include an alkyl portion where alkyl is as defined above and include an aryl portion where aryl is as defined above.
  • arylalkyl include, but are not limited to, benzyl, fluorobenzyl, chlorobenzyl, phenylethyl, phenylpropyl, fluorophenylethyl, chlorophenylethyl, thienylmethyl, thienylethyl, and thienylpropyl.
  • alkylaryl include, but are not limited to, toluene, ethylbenzene, propylbenzene, methylpyridine, ethylpyridine, propylpyridine and butylpyridine.
  • halogen shall include iodine, bromine, chlorine, and fluorine.
  • oxy means an oxygen (O) atom.
  • thio means a sulfur (S) atom.
  • oxo means “ ⁇ O”.
  • carbonyl means “C ⁇ O.”
  • substituted shall be deemed to include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.
  • any variable e.g., R 2 , R 3 , etc.
  • its definition in each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • Compounds of the present invention have been found to be tissue-selective modulators of the androgen receptor (SARMs).
  • SARMs tissue-selective modulators of the androgen receptor
  • compounds of the present invention may be useful to activate the function of the androgen receptor in a mammal, and in particular to activate the function of the androgen receptor in bone and/or muscle tissue and block or inhibit (“antagonize”) the function of the androgen receptor in the prostate of a male individual or in the uterus of a female individual.
  • the activation of the AR in bone can be assayed through stimulation of bone formation in a rodent model of osteoporosis, and the antagonism of the AR in the prostate can be assayed through observation of minimal effects on prostate growth in castrated rodents and antagonism of prostate growth induced by AR agonists, as detailed in the Examples.
  • a further aspect of the present invention is concerned with compounds of structural formula I that block the function of the androgen receptor in the prostate of a male individual or in the uterus of a female individual induced by AR agonists, but not in hair-growing skin or vocal cords, and activate the function of the androgen receptor in bone and/or muscle tissue, but not in organs which control blood lipid levels (e.g. liver).
  • the compounds of the present invention may be used to treat conditions which are caused by androgen deficiency or which can be ameliorated by androgen replacement, including, but not limited to osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, Alzheimer's disease, prostate cancer, cancer cachexia, muscular dystrophies, Alzheimer's disease, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
  • Treatment is effected by administration of a therapeutically effective amount of a compound of structural formula I to a mammal in need of such treatment.
  • these compounds are useful as ingredients in pharmaceutical compositions alone or in
  • the compounds of the present invention may be used to treat conditions in a male individual which are caused by androgen deficiency or which can be ameliorated by androgen replacement, including, but not limited to, osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, HIV-wasting, prostate cancer, cancer cachexia, obesity, aplastic and other anemias, muscular dystrophies, and Alzheimer's disease, alone or in combination with other active agents.
  • Treatment is effected by administration of a therapeutically effective amount of a compound of structural formula I to a male individual in need of such treatment.
  • the compounds of the present invention may be used to treat conditions in a female individual which are caused by androgen deficiency or which can be ameliorated by androgen replacement, including, but not limited to, osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, postmenopausal symptoms, periodontal disease, HIV-wasting, cancer cachexia, obesity, aplastic and other anemias, muscular dystrophies, Alzheimer's disease, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
  • Treatment is effected by administration of a therapeutically effective amount of a compound of structural formula I to a female individual in need of such treatment.
  • the compounds of structural formula I may also be employed as adjuncts to traditional androgen depletion therapy in the treatment of prostate cancer to restore bone, minimize bone loss, and maintain bone mineral density. In this manner, they may be employed together with traditional androgen deprivation therapy, including GnRH agonists/antagonists, such as those disclosed in P. Limonta, et al., “LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action,” Exp. Opin. Invest. Drugs, 10: 709-720 (2001); H. J. Stricker, “Luteinizing hormone-releasing hormone antagonists,” Urology, 58 (Suppl. 2A): 24-27 (2001); R. P.
  • the compounds of the present invention may also be employed in the treatment of pancreatic cancer, either for their androgen antagonist properties or as an adjunct to an antiandrogen, such as flutamide, 2-hydroxyflutamide (the active metabolite of flutamide), nilutamide, and bicalutamide (CasodexTM).
  • an antiandrogen such as flutamide, 2-hydroxyflutamide (the active metabolite of flutamide), nilutamide, and bicalutamide (CasodexTM).
  • compounds of the present invention can increase the number of blood cells, such as red blood cells and platelets, and can be used for treatment of hematopoietic disorders, such as aplastic anemia.
  • Representative compounds of the present invention typically display submicromolar binding affinity for the androgen receptor.
  • Compounds of this invention are therefore useful in treating mammals suffering from disorders related to androgen receptor function.
  • Pharmacologically effective amounts of the compound, including the pharmaceutically effective salts thereof are administered to the mammal, to treat disorders related to androgen receptor function, or which can be improved by the addition of additional androgen, such as osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, pancreatic cancer, Alzheimer's disease, inflammatory arthritis, and joint repair.
  • Racemic mixtures can be separated into their individual enantiomers by any of a number of conventional methods. These include chiral chromatography, derivatization with a chiral auxiliary followed by separation by chromatography or crystallization, and fractional crystallization of diastereomeric salts.
  • tissue-selective androgen receptor modulator refers to an androgen receptor ligand that mimics the action of a natural ligand in some tissues but not in others.
  • tissue-selective androgen receptor modulator refers to an androgen receptor ligand that mimics the action of a natural ligand in some tissues but not in others.
  • a “partial agonist” is an agonist which is unable to induce maximal activation of the receptor population, regardless of the amount of compound applied.
  • a “full agonist” induces full activation of the androgen receptor population at a given concentration.
  • a compound of the present invention which functions as an “antagonist” of the androgen receptor can bind to the androgen receptor and block or inhibit the androgen-associated responses normally induced by a natural androgen receptor ligand.
  • salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, lithium, magnesium, potassium, and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • basic ion exchange resins such as
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, malonic, mucic, nitric, pamoic, pantothenic, phosphoric, propionic, succinic, sulfuric, tartaric, p-toluenesulfonic acid, trifluoroacetic acid, and the like.
  • Particularly preferred are citric, fumaric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.
  • terapéuticaally effective amount means the amount the compound of structural formula I that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • pharmaceutically acceptable it is meant that the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not be deleterious to the recipient thereof.
  • administering a compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individual in need of treatment.
  • modulating a function mediated by the androgen receptor in a tissue selective manner is meant modulating a function mediated by the androgen receptor selectively (or discriminately) in anabolic (bone and/or muscular) tissue (bone and muscular) in the absence of such modulation at androgenic (reproductive) tissue, such as the prostate, testis, seminal vesicles, ovary, uterus, and other sex accessory tissues.
  • anabolic tissue bone and/or muscular tissue
  • at androgenic tissue such as the prostate, testis, seminal vesicles, ovary, uterus, and other sex accessory tissues.
  • the function of the androgen receptor in anabolic tissue is activated whereas the function of the androgen receptor in androgenic tissue is blocked or suppressed.
  • the administration of a compound of structural formula I in order to practice the present methods of therapy is carried out by administering an effective amount of the compound of structural formula I to the patient in need of such treatment or prophylaxis.
  • the need for a prophylactic administration according to the methods of the present invention is determined via the use of well-known risk factors.
  • the effective amount of an individual compound is determined, in the final analysis, by the physician in charge of the case, but depends on factors such as the exact disease to be treated, the severity of the disease and other diseases or conditions from which the patient suffers, the chosen route of administration, other drugs and treatments which the patient may concomitantly require, and other factors in the physician's judgment.
  • the daily dosage of a compound of structural formula I may be varied over a wide range from 0.01 to 1000 mg per adult human per day. Most preferably, dosages range from 0.1 to 200 mg/day.
  • the compositions are preferably provided in the form of tablets containing 0.01 to 1000 mg, particularly 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 3.0, 5.0, 6.0, 10.0, 15.0, 25.0, 50.0, 75, 100, 125, 150, 175, 180, 200, 225, and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the mammal to be treated.
  • the dose may be administered in a single daily dose or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, based on the properties of the individual compound selected for administration, the dose may be administered less frequently, e.g., weekly, twice weekly, monthly, etc. The unit dosage will, of course, be correspondingly larger for the less frequent administration.
  • the dosage administration When administered via intranasal routes, transdermal routes, by rectal or vaginal suppositories, or through an intravenous solution, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • Exemplifying the invention is a pharmaceutical composition comprising any of the compounds described above and a pharmaceutically acceptable carrier. Also exemplifying the invention is a pharmaceutical composition made by combining any of the compounds described above and a pharmaceutically acceptable carrier. An illustration of the invention is a process for making a pharmaceutical composition comprising combining any of the compounds described above and a pharmaceutically acceptable carrier.
  • Formulations of the tissue-selective androgen receptor modulator employed in the present method for medical use comprise a compound of structural formula I together with an acceptable carrier thereof and optionally other therapeutically active ingredients.
  • the carrier must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not being deleterious to the recipient subject of the formulation.
  • the present invention therefore, further provides a pharmaceutical formulation comprising a compound of structural formula I together with a pharmaceutically acceptable carrier thereof.
  • the formulations include those suitable for oral, rectal, intravaginal, topical or parenteral (including subcutaneous, intramuscular and intravenous administration). Preferred formulations are those suitable for oral administration.
  • the formulations may be presented in a unit dosage form and may be prepared by any of the methods known in the art of pharmacy. All methods include the step of bringing the active compound in association with a carrier which constitutes one or more ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound in association with a liquid carrier, a waxy solid carrier or a finely divided solid carrier, and then, if needed, shaping the product into the desired dosage form.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active compound; as a powder or granules; or a suspension or solution in an aqueous liquid or non-aqueous liquid, e.g., a syrup, an elixir, or an emulsion.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free flowing form, e.g., a powder or granules, optionally mixed with accessory ingredients, e.g., binders, lubricants, inert diluents, disintegrating agents or coloring agents.
  • Molded tablets may be made by molding in a suitable machine a mixture of the active compound, preferably in powdered form, with a suitable carrier.
  • Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethyl-cellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include, without limitation, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • Oral liquid forms such as syrups or suspensions in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl cellulose and the like, may be made by adding the active compound to the solution or suspension.
  • suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl cellulose and the like.
  • Additional dispersing agents which may be employed include glycerin and the like.
  • Formulations for vaginal or rectal administration may be presented as a suppository with a conventional carrier, i.e., a base that is nontoxic and nonirritating to mucous membranes, compatible with a compound of structural formula I, and is stable in storage and does not bind or interfere with the release of the compound of structural formula I.
  • Suitable bases include: cocoa butter (theobroma oil), polyethylene glycols (such as carbowax and polyglycols), glycol-surfactant combinations, polyoxyl 40 stearate, polyoxyethylene sorbitan fatty acid esters (such as Tween, Myi, and Arlacel), glycerinated gelatin, and hydrogenated vegetable oils.
  • a preservative such as methylparaben or propylparaben may be employed.
  • Topical preparations containing the active drug component can be admixed with a variety of carrier materials well known in the art, such as, e.g., alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, PPG2 myristyl-propionate, and the like, to form, e.g., alcoholic solutions, topical cleansers, cleansing creams, skin gels, skin lotions, and shampoos in cream or gel formulations.
  • carrier materials well known in the art, such as, e.g., alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, PPG2 myristyl-propionate, and the like, to form, e.g., alcoholic solutions, topical cleansers, cleansing creams, skin gels, skin lotions, and shampoos in cream or gel formulations.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinyl-pyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy-ethylaspartamidephenol, or polyethylene-oxide polylysine substituted with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • a drug for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • Formulations suitable for parenteral administration include formulations that comprise a sterile aqueous preparation of the active compound which is preferably isotonic with the blood of the recipient. Such formulations suitably comprise a solution or suspension of a compound that is isotonic with the blood of the recipient subject. Such formulations may contain distilled water, 5% dextrose in distilled water or saline and the active compound. Often it is useful to employ a pharmaceutically and pharmacologically acceptable acid addition salt of the active compound that has appropriate solubility for the solvents employed. Useful formulations also comprise concentrated solutions or solids comprising the active compound which on dilution with an appropriate solvent give a solution suitable for parenteral administration.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.
  • biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.
  • the pharmaceutical composition and method of the present invention may further comprise other therapeutically active compounds usually applied in the treatment of the above mentioned conditions, including osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, post-menopausal- symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, Alzheimer's disease, inflammatory arthritis, and joint repair.
  • other therapeutically active compounds usually applied in the treatment of the above mentioned conditions, including osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, post-menopausal- symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, Alzheimer's disease
  • the compounds of the present invention may be administered in combination with a bone-strengthening agent selected from antiresorptive agents, osteoanabolic agents, and other agents beneficial for the skeleton through mechanisms which are not precisely defined, such as calcium supplements, flavonoids, and vitamin D analogs.
  • a bone-strengthening agent selected from antiresorptive agents, osteoanabolic agents, and other agents beneficial for the skeleton through mechanisms which are not precisely defined, such as calcium supplements, flavonoids, and vitamin D analogs.
  • the conditions of periodontal disease, bone fracture, and bone damage following bone reconstructive surgery may also benefit from these combined treatments.
  • the compounds of the instant invention may be effectively administered in combination with effective amounts of other agents such as estrogens, bisphosphonates, SERMs, cathepsin K inhibitors, xvp3 integrin receptor antagonists, vacuolar ATPase inhibitors, the polypeptide osteoprotegerin, antagonists of VEGF, thiazolidinediones, calcitonin, protein kinase inhibitors, parathyroid hormone (PMH) and analogs, calcium receptor antagonists, growth hormone secretagogues, growth hormone releasing hormone, insulin-like growth factor, bone morphogenetic protein (BMP), inhibitors of BMP antagonism, prostaglandin derivatives, fibroblast growth factors, vitamin D and derivatives thereof, vitamin K and derivatives thereof, soy isoflavones, calcium salts, and fluoride salts.
  • other agents such as estrogens, bisphosphonates, SERMs, cathepsin K inhibitors, xvp3 integrin receptor antagonists, vacuolar ATPa
  • a compound of the instant invention may be effectively administered in combination with an effective amount of a bone-strengthening agent selected from the group consisting of estrogen or an estrogen derivative, alone or in combination with a progestin or progestin derivative; a bisphosphonate; an antiestrogen or a selective estrogen receptor modulator; an ⁇ v ⁇ 3 integrin receptor antagonist; a cathepsin K inhibitor; an osteoclast vacuolar ATPase inhibitor; calcitonin; and osteoprotegerin.
  • a bone-strengthening agent selected from the group consisting of estrogen or an estrogen derivative, alone or in combination with a progestin or progestin derivative; a bisphosphonate; an antiestrogen or a selective estrogen receptor modulator; an ⁇ v ⁇ 3 integrin receptor antagonist; a cathepsin K inhibitor; an osteoclast vacuolar ATPase inhibitor; calcitonin; and osteoprotegerin.
  • the activity of the compounds of the present invention are distinct from that of the anti-resorptive agents: estrogens, bisphosphonates, SERMs, calcitonin, cathepsin K inhibitors, vacuolar ATPase inhibitors, agents interfering with the RANK/RANKL/Osteoprotegerin pathway, p38 inhibitors or any other inhibitors of osteoclast generation or osteoclast activation.
  • the compounds of structural formula I stimulate bone formation, acting preferentially on cortical bone, which is responsible for a significant part of bone strength.
  • the thickening of cortical bone substantially contributes to a reduction in fracture risk, especially fractures of the hip.
  • tissue-selective androgen receptor modulators of structural formula I with anti-resorptive agents such as estrogen, bisphosphonates, antiestrogens, SERMs, calcitonin, ⁇ v ⁇ 3 integrin receptor antagonists, HMG-CoA reductase inhibitors, vacuolar ATPase inhibitors, and cathepsin K inhibitors is particularly useful because of the complementarity of the bone anabolic and antiresorptive actions.
  • anti-resorptive agents such as estrogen, bisphosphonates, antiestrogens, SERMs, calcitonin, ⁇ v ⁇ 3 integrin receptor antagonists, HMG-CoA reductase inhibitors, vacuolar ATPase inhibitors, and cathepsin K inhibitors is particularly useful because of the complementarity of the bone anabolic and antiresorptive actions.
  • Bone antiresportive agents are those agents which are known in the art to inhibit the resorption of bone and include, for example, estrogen and estrogen derivatives which include steroidal compounds having estrogenic activity such as, for example, 17 ⁇ -estradiol, estrone, conjugated estrogen (PREMARIN®), equine estrogen, 17 ⁇ -ethynyl estradiol, and the like.
  • the estrogen or estrogen derivative may be employed alone or in combination with a progestin or progestin derivative.
  • progestin derivatives are norethindrone and medroxy-progesterone acetate.
  • Bisphosphonates are also bone anti-resorptive agents.
  • Bisphosphonate compounds which may also be employed in combination with a compound of structural formula I of the present invention include:
  • the bisphosphonate is selected from the group consisting of alendronate, clodronate, etidronate, ibandronate, incadronate,. minodronate, neridronate, olpadronate, pamidronate, piridronate, risedronate, tiludronate, and zoledronate, and pharmaceutically acceptable salts thereof, and mixtures thereof.
  • the bisphosphonate is selected from the group consisting of alendronate, risedronate, zoledronate, ibandronate, tiludronate, and clodronate.
  • the bisphosphonate is alendronate, pharmaceutically acceptable salts and hydrates thereof, and mixtures thereof.
  • a particular pharmaceutically acceptable salt of alendronate is alendronate monosodium.
  • Pharmaceutically acceptable hydrates of alendronate monosodium include the monohydrate and the trihydrate.
  • a particular pharmaceutically acceptable salt of risedronate is risedronate monosodium.
  • Pharmaceutically acceptable hydrates of risedronate monosodium include the hemi-pentahydrate.
  • alendronic acid includes the related bisphosphonic acid forms, pharmaceutically acceptable salt forms, and equilibrium mixtures of these. It includes crystalline, hydrated crystalline, and amorphous forms of alendronic acid and pharmaceutically acceptable salts thereof. It specifically includes anhydrous alendronate monosodium, alendronate monosodium monohydrate, and alendronate monosodium trihydrate.
  • antiestrogenic compounds such as raloxifene (see, e.g., U.S. Pat. No. 5,393,763), clomiphene, zuclomiphene, enclomiphene, nafoxidene, CI-680, CI-628, CN-55,945-27, Mer-25, U-11,555A, U-100A, and salts thereof, and the like (see, e.g., U.S. Pat. Nos. 4,729,999 and 4,894,373) may be employed in combination with a compound of structural formula I in the methods and compositions of the present invention.
  • SERMs selective estrogen receptor modulators
  • agents known in the art to prevent bone loss by inhibiting bone resorption via pathways believed to be similar to those of estrogens.
  • SERMs selective estrogen receptor modulators
  • These agents may be used in combination with the compounds of the present invention to beneficially treat bone disorders including osteoporosis.
  • Such agents include, for example, tamoxifen, raloxifene, lasofoxifene, toremifene, azorxifene, EM-800, EM-652, TSE 424, clomiphene, droloxifene, idoxifene, and levormeloxifene [Goldstein, et al., “A pharmacological review of selective estrogen receptor modulators,” Human Reproduction Update, 6: 212-224 (2000), and Lufkin, et al., “The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis,” Rheumatic Disease Clinics of North America, 27: 163-185 (2001)].
  • ⁇ v ⁇ 3 Integrin receptor antagonists suppress bone resorption and may be employed in combination with the tissue selective androgen receptor modulators of structural formula I for the treatment of bone disorders including osteoporosis.
  • Peptidyl as well as peptidomimetic antagonists of the ⁇ v ⁇ 3 integrin receptor have been described both in the scientific and patent literature. For example, reference is made to W. J. Hoekstra and B. L. Poulter, Curr. Med. Chem.
  • Keenan et al. “Benzimidazole Derivatives As Arginine Mimetics in 1,4-Benzodiazepine Nonpeptide Vitronectin Receptor ( ⁇ v ⁇ 3) Antagonists,” Bioorg. Med. Chem. Lett. 8: 3165-3170 (1998); and R. M. Keenan et al., “Discovery of an midazopyridine-Containing 1,4-Benzodiazepine Nonpeptide Vitronectin Receptor ( ⁇ v ⁇ 3) Antagonist With Efficacy in a Restenosis Model,” Bioorg. Med. Chem. Lett. 8: 317 ⁇ -3176 (1998).
  • benzazepine, benzodiazepine and benzocycloheptene ⁇ v ⁇ 3 integrin receptor antagonists are described in the following patent publications: WO 96/00574, WO 96/00730, WO 96/06087, WO 96/26190, WO 97/24119, WO 97/24122, WO 97/24124, WO 98/14192, WO 98/15278, WO 99/05107, WO 99/06049, WO 99/15170, WO 99/15178, WO 99/15506, and U.S. Pat. No. 6,159,964, and WO 97/34865.
  • ⁇ v ⁇ 3 integrin receptor antagonists having dibenzocycloheptene, dibenzocycloheptane and dibenzoxazepine scaffolds have been described in WO 97/01540, WO 98/30542, WO 99/11626, WO 99/15508, WO 00/33838, U.S. Pat. Nos. 6,008,213, and 6,069,158.
  • Other osteoclast integrin receptor antagonists incorporating backbone conformational ring constraints have been described in the patent literature.
  • Cathepsin K formerly known as cathepsin O2
  • cathepsin O2 is a cysteine protease and is described in PCT International Application Publication No. WO 96/13523, published May 9, 1996; U.S. Pat. No. 5,501,969, issued Mar. 3, 1996; and U.S. Pat. No. 5,736,357, issued Apr. 7, 1998, all of which are incorporated by reference herein in their entirety.
  • Cysteine proteases specifically cathepsins, are linked to a number of disease conditions, such as tumor metastasis, inflammation, arthritis, and bone remodeling. At acidic pH's, cathepsins can degrade type-I collagen.
  • Cathepsin protease inhibitors can inhibit osteoclastic bone resorption by inhibiting the degradation of collagen fibers and are thus useful in the treatment of bone resorption diseases, such as osteoporosis.
  • HMG-CoA reductase inhibitors Members of the class of HMG-CoA reductase inhibitors, known as the “statins,” have been found to trigger the growth of new bone, replacing bone mass lost as a result of osteoporosis (see The Wall Street Journal, Friday, Dec. 3, 1999, page B1). Therefore, the statins hold promise for the treatment of bone resorption.
  • HMG-CoA reductase inhibitors include statins in their lactonized or dihydroxy open acid forms and pharmaceutically acceptable salts and esters thereof, including but not limited to lovastatin (see U.S. Pat. No. 4,342,767); simvastatin (see U.S. Pat. No.
  • Osteoclast vacuolar ATPase inhibitors also called proton pump inhibitors, may also be employed together with the tissue selective androgen receptor modulators of structural formula I.
  • the proton ATPase which is found on the apical membrane of the osteoclast has been reported to play a significant role in the bone resorption process. Therefore, this proton pump represents an attractive target for the design of inhibitors of bone resorption which are potentially useful for the treatment and prevention of osteoporosis and related metabolic diseases [see C. Farina et al., “Selective inhibitors of the osteoclast vacuolar proton ATPase as novel bone antiresorptive agents,” DDT, 4: 163-172 (1999)].
  • VEGF angiogenic factor
  • PPAR ⁇ activators include the glitazones, such as troglitazone, pioglitazone, rosiglitazone, and BRL 49653.
  • Calcitonin may also be employed together with the tissue selective androgen receptor modulator of structural formula I. Calcitonin is preferentially employed as salmon nasal spray (Azra et al., Calcitonin. 1996. In: J. P. Bilezikian, et al., Ed., Principles of Bone Biology, San Diego: Academic Press; and Silverman, “Calcitonin,” Rheumatic Disease Clinics of North America, 27: 187-196, 2001)
  • Protein kinase inhibitors may also be employed together with the tissue selective androgen receptor modulators of structural formula I.
  • Kinase inhibitors include those disclosed in WO 01/17562 and are in one embodiment selected from inhibitors of p38.
  • Specific embodiments of p38 inhibitors useful in the present invention include SB 203580 Badger et al., “Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock, and immune function,” J. Pharmacol. Exp. Ther., 279: 1453-1461 (1996)].
  • Osteoanabolic agents are those agents that are known in the art to build bone by increasing the production of the bone protein matrix.
  • Such osteoanabolic agents include, for example, the various forms of parathyroid hormone (PHi) such as naturally occurring PTH (1-84), PTH (1-34), analogs thereof, native or with substitutions and particularly parathyroid hormone subcutaneous injection.
  • PTH has been found to increase the activity of osteoblasts, the cells that form bone, thereby promoting the synthesis of new bone ( Modern Drug Discovery, Vol. 3, No. 8, 2000).
  • women in combined PTH-estrogen therapy exhibited a 12.8% increase in spinal bone mass and a 4.4% increase in total hip mass.
  • PTH and fragments thereof may prove to be efficacious in the treatment of osteoporosis alone or in combination with other agents, such as the tissue selective androgen receptor modulators of the present invention.
  • An injectable recombinant form of human PTH, Forteo (teriparatide) has received regulatory approval in the U.S. for the treatment of osteoporosis.
  • Also useful in combination with the SARMs of the present invention are calcium receptor antagonists which induce the secretion of PTH as described by Gowen et al., in “Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats,” J. Clin. Invest. 105: 1595-604 (2000).
  • Growth hormone secretagogues, growth hormone, growth hormone releasing hormone and the like are also osteoanabolic agents which may be employed with the compounds according to structural formula I for the treatment of osteoporosis.
  • Representative growth hormone secretagogues are disclosed in U.S. Pat. No. 3,239,345; U.S. Pat. No. 4,036,979; U.S. Pat. No. 4,411,890; U.S. Pat. No. 5,206,235; U.S. Pat. No. 5,283,241; U.S. Pat. No. 5,284,841; U.S. Pat. No. 5,310,737; U.S. Pat. No. 5,317,017; U.S. Pat. No. 5,374,721; U.S. Pat. No.
  • Insulin-like growth factor may also be employed together with the tissue selective androgen receptor modulators of structural formula I.
  • Insulin-like growth factors may be selected from Insulin-like Growth Factor I, alone or in combination with IGF binding protein 3 and IGF II [See Johannson and Rosen, “The IGFs as potential therapy for metabolic bone diseases,” 1996, In: Bilezikian, et al., Ed., Principles of Bone Biolog, San Diego: Academic Press; and Ghiron et al., “Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women,” J. Bone Miner. Res. 10: 1844-1852 (1995)].
  • Bone morphogenetic protein may also be employed together with the tissue selective androgen receptor modulators of structural formula I.
  • Bone morphogenetic protein includes BMP 2, 3, 5, 6, 7, as well as related molecules TGF beta and GDF 5 (Rosen et al., “Bone morphogenetic proteins,” 1996. In: J. P. Bilezikian, et al., Ed., Principles of Bone Biology, San Diego: Academic Press; and Wang E A, “Bone morphogenetic proteins (BMPs): therapeutic potential in healing bony defects,” Trends Biotechnol., 11: 379-383 (1993)].
  • BMP antagonist inhibitors are in one embodiment selected from inhibitors of the BMP antagonistsSOST, noggin, chordin, gremlin, and dan [Massague and Chen, “Controlling TGF-beta signaling,” Genes Dev., 14: 627-644, 2000; Aspenberg et al., “The bone morphogenetic proteins antagonist Noggin inhibits membranous ossification,” J. Bone Miner. Res.
  • the tissue-selective androgen receptor modulators of the present invention may also be combined with the polypeptide osteoprotegerin for the treatment of conditions associated with bone loss, such as osteoporosis.
  • osteoprotegerin is mammalian osteoprotegerin and more preferably human osteoprotegerin.
  • the polypeptide osteoprotegerin a member ot the tumor necrosis factor receptor superfamily, is useful to treat bone diseases characterized by increased bone loss, such as osteoporosis.
  • U.S. Pat. No. 6,288,032 which is incorporated by reference herein in its entirety.
  • Prostaglandin derivatives may also be employed together with the tissue selective androgen receptor modulators of structural formula I.
  • Prostaglandin derivatives are in one embodiment selected from agonists of prostaglandin receptor EP1, EP2, EP4, FP and IP or a derivative thereof [Pilbeam et al., “Prostaglandins and bone metabolism,” 1996. In: Bilezikian, et al. Ed. Principles of Bone Biology, San Diego: Academic Press; Weinreb et al., “Expression of the prostaglandin E(2) (PGE(2)) receptor subtype EP(4) and its regulation by PGE(2) in osteoblastic cell lines and adult rat bone tissue,” Bone, 28: 275-281 (2001)].
  • Fibroblast growth factors may also be employed together with the tissue selective androgen receptor modulators of structural formula I.
  • Fibroblast growth factors include aFGF, bFGF and related peptides with FGF activity [urley Florkiewicz, “Fibroblast growth factor and vascular endothelial growth factor families,” 1996. In: J. P. Bilezikian, et al., Ed. Principles of Bone Biology, San Diego: Academic Press].
  • Vitamin D and vitamin D derivatives may also be employed together with the tissue selective androgen receptor modulator of structural formula I.
  • Vitamin D and vitamin D derivatives include natural vitamin D, 25-OH-vitamin D3, 1 ⁇ ,25(OH) 2 vitamin D3, 1 ⁇ -OH-vitamin D3, 1 ⁇ -OH-vitamin D2, dihydrotachysterol, 26,27-F6-1 ⁇ ,25(OH) 2 vitamin D3, 19-nor-1 ⁇ ,25(OH) 2 vitamin D3, 22-oxacalcitriol, calcipotriol, 1 ⁇ ,25(OH)2-16-ene-23-yne-vitamin D3 (Ro 23-7553), EB1089, 20-epi-1 ⁇ ,25(OH) 2 vitamin D3, KH1060, ED71, 1 ⁇ ,24(S)—(OH) 2 vitamin D3, 1 ⁇ ,24(R)—(OH) 2 vitamin D3 [See, Jones G., “Pharmacological mechanisms of therapeutics: vitamin D and analogs,” 1996. In: J. P
  • Vitamin K and vitamin K derivatives may also be employed together with the tissue selective androgen receptor modulators of structural formula I.
  • Vitamin K and vitamin K derivatives include menatetrenone (vitamin K2) [see Shiraki et al., “Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis,” J. Bone Miner. Res., 15: 515-521 (2000)].
  • Soy isoflavones including ipriflavone, may be employed together with the tissue selective androgen receptor modulators of structural formula I.
  • Fluoride salts including sodium fluoride (NaF) and monosodium fluorophosphate (MFP), may also be employed together with the tissue selective androgen receptor modulators of structural formula I.
  • Dietary calcium supplements may also be employed together with the tissue selective androgen receptor modulators of structural formula I. Dietary calcium supplements include calcium carbonate, calcium citrate, and natural calcium salts (Heaney. Calcium. 1996. In: J. P. Bilezikian, et al., Ed., Principles of Bone Biology, San Diego: Academic Press).
  • Daily dosage ranges for bone resorption inhibitors, osteoanabolic agents and other agents which may be used to benefit the skeleton when used in combination with a compound of structural formula I are those which are known in the art.
  • the daily dosage range for the tissue selective androgen receptor modulator of structural formula I is 0.01 to 1000 mg per adult human per day, more preferably from 0.1 to 200 mg/day.
  • adjustments to decrease the dose of each agent may be made due to the increased efficacy of the combined agent.
  • a bisphosphonate when employed, dosages of 2.5 to 100 mg/day (measured as the free bisphosphonic acid) are appropriate for treatment, more preferably 5 to 20 mg/day, especially about 10 mg/day. Prophylactically, doses of about 2.5 to about 10 mg/day and especially about 5 mg/day should be employed. For reduction in side-effects, it may be desirable to administer the combination of a compound of structural formula I and the bisphosphonate once a week. For once weekly administration, doses of about 15 mg to 700 mg per week of bisphosphonate and 0.07 to 7000 mg of a compound of structural formula I may be employed, either separately, or in a combined dosage form. A compound of structural formula I may be favorably administered in a controlled-release delivery device, particularly for once weekly administration.
  • the compounds of structural formula I may be effectively administered in combination with one or more additional active agents.
  • the additional active agent or agents can be lipid-altering compounds such as HMG-CoA reductase inhibitors, or agents having other pharmaceutical activities, or agents that have both lipid-altering effects and other pharmaceutical activities.
  • HMG-CoA reductase inhibitors include statins in their lactonized or dihydroxy open acid forms and pharmaceutically acceptable salts and esters thereof, including but not limited to lovastatin (see U.S. Pat. No. 4,342,767); simvastatin (see US Pat. No.
  • Additional active agents which may be employed in combination with a compound of structural formula I include, but are not limited to, HMG-CoA synthase inhibitors; squalene epoxidase inhibitors; squalene synthetase inhibitors (also known as squalene synthase inhibitors), acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitors including selective inhibitors of ACAT-1 or ACAT-2 as well as dual inhibitors of ACAT-1 and -2; microsomal triglyceride transfer protein (NffP) inhibitors; probucol; niacin; cholesterol absorption inhibitors, such as SCH-58235, also known as ezetimibe and 1-(4-fluorophenyl)-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl)]4(S)-(4-hydroxyphenyl)-2-azetidinone, which is described in U.S
  • PPAR ⁇ peroxisome proliferator activated receptor gamma
  • glitazones for example troglitazone, pioglitazone and rosiglitazone and, including those compounds included within the structural class known as thiazolidinediones as well as those PPAR ⁇ agonists outside the thiazolidinedione structural class
  • PPAR ⁇ agonists such as clofibrate, fenofibrate including micronized fenofibrate, and gemfibrozil
  • PPAR dual ⁇ / ⁇ agonists vitamin B 6 (also known as pyridoxine) and the pharmaceutically acceptable salts thereof such as the HC
  • EMG-CoA reductase inhibitors when used in combination with the compounds of structural formula I correspond to those which are known in the art.
  • the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • the instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term “administering” is to be interpreted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other agents useful for treating diseases caused by androgen deficiency or that can be ameliorated by addition of androgen.
  • the compounds of the present invention can be prepared according to the procedures denoted in the following reaction Schemes and Examples or modifications thereof using readily available starting materials, reagents, and conventional procedures or variations thereof well-known to a practitioner of ordinary skill in the art of synthetic organic chemistry. Specific definitions of variables in the Schemes are given for illustrative purposes only and are not intended to limit the procedures described.
  • Step B 4-Methyl-3-oxo-4-aza-5 ⁇ -androst-5-en-17 ⁇ -carboxylic acid methyl ester (1-3)
  • Step C 6-Bromo-4-methyl-3-oxo-4-aza-5 ⁇ -androst-5-en-17 ⁇ -carboxylic acid methyl ester (1-4)
  • Step D 4-methyl-6-methyl-3-oxo-4-aza-5 ⁇ -androst-5-en-17 ⁇ -carboxylic acid methyl ester (1-5)
  • Step E 4-methyl-6-methyl-3-oxo-4-aza-5 ⁇ -androst-5-en-17 ⁇ -carboxylic acid (1-6)
  • Examples 2-84 in Table 1 were prepared in a similar manner as Compound 2-2, (Example 2 in Table 1), but using the appropriate R 2 R 3 NH amine to generate the final desired carboxamide.
  • Examples 86 -130 in Table 2 were prepared in a similar manner as Compound 3-1 (Example 85 in Table 2), but using the appropriate amine to generate the final desired carboxamide.
  • TABLE 2 MASS SPECTRUM Measured EX NR 2 R 3 NAME [M + 1] 85 N-(benzimidazol-2- ylmethyl)-4-methyl-6- methyl-3-oxo-4-aza-5 ⁇ - androst-5-en-17 ⁇ - carboxamide 475.3054 86 N-(2-fluoro-6- chlorophenylmethyl)-4- methyl-6-methyl-3-oxo-4- aza-5 ⁇ -androst-5-en-17 ⁇ - carboxamide 487.0 87 N-((R)- phenylmethylmethyl)-4- methyl-6-methyl-3-oxo-4- aza-5 ⁇ -androst-5-en-17 ⁇ - carboxamide 449.1 88 N-((S)- phenylmethylmethyl)4- methyl-6-methyl-3-oxo-4
  • Step A Methyl (3S,3aS,6R)-6-(3-methoxy-3-oxopropyl)-3a,6-dimethyl-7-oxododecahydro-1H-cyclopenta[a]naphthalene-3-carboxylate (4-1)
  • Step B 3-[(3S,3aS,6R)-3-(methoxycarbonyl)-3a,6-dimethyl-8-methylene-7-oxododecahydro-1H-cyclopenta[a]naphthalen-6-yl]propanoic acid (4-2)
  • Step C 3-[(3S,3aS,6R)-8,8-ethylene-3-(methoxycarbonyl)-3a,6-dimethyl-7-oxododecahydro-1H-cyclopenta[a]naphthalen-6 -yl] propanoic acid (4-3).
  • Step D 6,6-Ethylene-5-hydroxy-3-oxo-4-aza-5 ⁇ -androst-17 ⁇ -carboxylic acid methyl ester (4-4)
  • Step E 6,6-Ethylene-3-oxo4-aza-5 ⁇ -androst-17 ⁇ -carboxylic acid methyl ester (4-5)
  • Step F 6,6-Ethylene-3-oxo-4-aza-5 ⁇ -androst-17 ⁇ -carboxylic acid (4-6)
  • Step G S-(pyridin-2-yl)-6,6-Ethylene-3-oxo-4-aza-5 ⁇ -androst-17 ⁇ -carbothioate(4-7)
  • Step H N-(2′,3′-Difluoro-phenyl)-6,6-Ethylene-3-oxo-4-aza-5 ⁇ -androst- 17 ⁇ -carboxamide (4-8)
  • Examples 132-156 in Table 3 were prepared in a similar manner as Compound 4-8 (Example 131 in Table 3) using the appropriate amine to generate the final desired carboxamide. Some of these examples were prepared using the reaction conditions similar to those in Example 84 to couple compound 46 with the appropriate amine.
  • Step A 6,6-Ethylene-3-oxo-4-aza-4-methyl-5 ⁇ -androst-17 ⁇ -carboxylic acid methyl ester (5-1)
  • Step B 6,6-Ethylene-3-oxo-4-aza-4-methyl-5 ⁇ -androst-17 ⁇ -carboxylic acid (5-2)
  • Step C S-(Pyridin-2-yl)-6,6-Ethylene-3-oxo-4-aza-4-methyl-5 ⁇ -androst-17 ⁇ -carbothioate (5-3)
  • Step D N-(2′,3′-Difluoro-phenyl)-6,6-Ethylene-3-oxo-4-aza-4-methyl-5 ⁇ -androst-17 ⁇ -carboxamide (5-4)
  • Examples 158-168 in Table 4 were prepared in a similar manner as Compound 54 (Example 157 in Table 4) but using the appropriate amine to generate the final desired carboxamide.
  • TABLE 4 MASS SPECTRUM Measured EX NHR NAME [M + 1] 157 N-(2,3-Difluoro- phenyl)-6,6-Ethylene- 3-oxo-4-aza-4- methyl-5 ⁇ -androst- 17 ⁇ -carboxamide 471.2812 158 N-(2-chlorophenyl)- 6,6-Ethylene-3-oxo- 4-aza-4-methyl-5 ⁇ - androst-17 ⁇ - carboxamide 469.2605 159 N-(2,6- dichlorophenyl)-6,6- Ethylene-3-oxo-4- aza-4-methyl-5 ⁇ - androst-17 ⁇ - carboxamide 503.2228 160 N-(2-fluorophenyl)- 6,6-Ethylene-3-oxo- 4-aza-4-
  • an oral composition of a compound of this invention 50 mg of a compound of the present invention is formatted with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0 hard gelatin capsule.
  • Transdermal Patch Formulation Ingredient Amount Compound of formula I 40 g Silicone fluid 45 g Colloidal silicone dioxide 2.5 g The silicone fluid and compound of structural formula I are mixed together and the colloidal silicone dioxide is added to increase viscosity. The material is then dosed into a subsequently heat sealed polymeric laminate comprised of the following: polyester release liner, skin contact adhesive composed of silicone or acrylic polymers, a control membrane which is a polyolefin (e.g. polyethylene, polyvinyl acetate or polyurethane), and an impermeable backing membrane made of a polyester multilaminate. The resulting laminated sheet is then cut into 10 cm 2 patches. For 100 Patches.
  • Injectable solution Ingredient Amount Compound of structural formula I 5 g Buffering agents q.s. Propylene glycol 400 mg Water for injection 600 mL The compound of structural formula I and buffering agents are dissolved in the propylene glycol at about 50° C. The water for injection is then added with stirring and the resulting solution is filtered, filled into ampules, sealed and sterilized by autoclaving. For 1000 Ampules.
  • Injectable solution Ingredient Amount Compound of structural formula I 5 g Buffering agents q.s. Magnesium sulfate heptahydrate 100 mg Water for injection 880 mL The compound of structural formula I, magnesium sulfate heptahydrate and buffering agents are dissolved in the water for injection with stirring, and the resulting solution is filtered, filled into ampoules, sealed and sterilized by autoclaving. For 1000 Ampoules.
  • tissue selective androgen receptor modulators of the present invention were used to characterize the activity of the tissue selective androgen receptor modulators of the present invention.
  • Molybdate Molybdic Acid (Sigma, M1651)
  • the MDA cells When the MDA cells are 70 to 85% confluent, they are detached as described above, and collected by centrifuging at 1000 g for 10 min at 4° C. The cell pellet is washed twice with TEGM (10 mM Tris-HCl, 1 mM EDTA, 10% glycerol, 1 mM beta-mercaptoethanol, 10 mM Sodium Molybdate, pH 7.2). After the final wash, the cells are resuspended in TEGM at a concentration of 10 7 cells/mL. The cell suspension is snap frozen in liquid nitrogen or ethanol/dry ice bath and transferred to ⁇ 80° C. freezer on dry ice.
  • TEGM 10 mM Tris-HCl, 1 mM EDTA, 10% glycerol, 1 mM beta-mercaptoethanol, 10 mM Sodium Molybdate, pH 7.2
  • the frozen samples are left on ice-water to just thaw ( ⁇ 1 hr). Then the samples are centrifuged at 12,500 g to 20,000 g for 30 min at 4° C. The supernatant is used to set-up assay right away. If using 50 ⁇ L of supernatant, the test compound can be prepared in 50 ⁇ L of the TEGM buffer.
  • 1 ⁇ TEGM buffer is prepared, and the isotope-containing assay mixture is prepared in the following order: EtOH (2% final concentration in reaction), 3 H-R1881 or 3 H-DHT (0.5 nM final Conc. in reaction) and 1 ⁇ TEGM.
  • EtOH 20% final concentration in reaction
  • 3 H-R1881 or 3 H-DHT 0.5 nM final Conc. in reaction
  • 1 ⁇ TEGM 1 ⁇ TEGM buffer
  • 25 ⁇ L of 3 H-R1881 trace and 25 ⁇ L compound solution are first mixed together, followed by addition of 50 ⁇ L receptor solution.
  • the reaction is gently mixed, spun briefly at about 200 rpm and incubated at 4° C. overnight.
  • 100 ⁇ L of 50% HAP slurry is prepared and added to the incubated reaction which is then vortexed and incubated on ice for 5 to 10 minutes.
  • the reaction mixture is vortexed twice more to resuspend HAP while incubating reaction.
  • the samples in 96-well format are then washed in wash buffer using The FilterMateTM Universal Harvester plate washer (Packard). The washing process transfers HAP pellet containing ligand-bound expressed receptor to Unifilter-96 GF/B filter plate (Packard).
  • IC 50 s are calculated using R1881 as a reference.
  • Tissue selective androgen receptor modulators of the present invention displayed IC 50 values of 1 micromolar or less.
  • HepG2 cells are cultured in phenol red free MEM containing 10% charcoal-treated FCS at 37C with 5% CO 2 .
  • cells are plated at 10,000 cells/well in 96 well white, clear bottom plates. Twenty four hours later, cells are co-transfected with a MMP1 promoter-luciferase reporter construct and a rhesus monkey expression construct (50:1 ratio) using FuGENE6 transfection reagent, following the protocol recommended by manufacturer.
  • the MMP1 promoter-luciferase reporter construct is generated by insertion of a human MMP1 promoter fragment ( ⁇ 179/+63) into pGL2 luciferase reporter construct (Promega) and a rhesus monkey AR expression construct is generated in a CMV-Tag2B expression vector (Stratagene). Cells are further cultured for 24 hours and then treated with test compounds in the presence of 100 nM phorbol-12-myristate-13-acetate (PMA), used to increase the basal activity of MMP1 promoter.
  • PMA phorbol-12-myristate-13-acetate
  • the compounds are added at this point, at a range of 1000 nM to 0.03 nM, 10 dilutions, at a concentration on 10 ⁇ , ⁇ fraction (1/10) ⁇ th volume (example: 10 microliters of ligand at 10 ⁇ added to 100 microliters of media already in the well).
  • Cells are further cultured for an additional 48 hours.
  • Cells are then washed twice with PBS and lysed by adding 70 ⁇ L of Lysis Buffer (1 ⁇ , Promega) to the wells.
  • the luciferase activity is measured in a 96-well format using a 1450 Microbeta Jet (Perkin Elmer) luminometer.
  • Test compounds Activity of test compounds is presented as suppression of luciferase signal from the PMA-stimulated control levels. EC 50 and Emax values are reported. Tissue selective androgen receptor modulators of the present invention activate repression typically with submicromolar EC 50 values and Emax values greater than about 50%.
  • This assay assesses the ability of AR agonists to induce the interaction between the N-terminal domain (NTD) and C-terminal domain (CTD) of rhAR that reflects the in vivo virilizing potential mediated by activated androgen receptors.
  • NTD N-terminal domain
  • CTD C-terminal domain
  • the interaction of NTD and CTD of rhAR is quantified as ligand induced association between a Gal4DBD-rhARCTD fusion protein and a VP16-rhARNTD fusion protein as a mammalian two-hybrid assay in CV-1 monkey kidney cells.
  • CV-1 cells are trypsinized and counted, and then plated at 20,000 cells/well in 96-well plates or larger plates (scaled up accordingly) in DMEM+10% FCS.
  • CV-1 cells are cotransfected with pCBB1 (Gal4DBD-rhARLBD fusion construct expressed under the SV40 early promoter), pCBB2 (VP16 -rhAR NTD fusion construct expressed under the SV40 early promoter) and pFR (Gal4 responsive luciferase reporter, Promega) using LIPOFECTAMINE PLUS reagent (GIBCO-BRL) following the procedure recommended by the vendor.
  • pCBB1 Gal4DBD-rhARLBD fusion construct expressed under the SV40 early promoter
  • pCBB2 VP16 -rhAR NTD fusion construct expressed under the SV40 early promoter
  • pFR Gal4 responsive luciferase reporter, Promega
  • DNA admixture of 0.05 ⁇ g pCBB1, 0.05 ⁇ g pCBB2 and 0.1 ⁇ g of pFR is mixed in 3.4 ⁇ L OPTI-MEM (GIBCO-BRL) mixed with “PLUS Reagent” (1.6 ⁇ L, GIBCO-BRL) and incubated at room temperature (RT) for 15 min to form the pre-complexed DNA.
  • LIPOFECTAMINE Reagent (GlBCO-BRL) is diluted into 4.6 ⁇ L OPTI-MEM in a second tube and mixed to form the diluted LIPOFECTAMINE Reagent.
  • the pre-complexed DNA (above) and the diluted LIPOFECTAMINE Reagent (above) are combined, mixed and incubated for 15 min at RT.
  • the medium on the cells is replaced with 40 ⁇ L/well OPTI-MEM, and 10 ⁇ L DNA-lipid complexes are added to each well.
  • the complexes are mixed into the medium gently and incubated at 37° C. at 5% CO 2 for 5h.
  • test compounds are added at the desired concentration(s) (1 nM-10 ⁇ M). Forty eight hours later, luciferase activity is measured using LUC-Screen system (TROPIX) following the manufacturer's protocol.
  • TROPIX LUC-Screen system
  • the assay is conducted directly in the wells by sequential addition of 50 ⁇ L each of assay solution 1 followed by assay solution 2. After incubation for 40 minutes at room temperature, luminescence is directly measured with 2-5 second integration.
  • Activity of test compounds is calculated as the Emax relative to the activity obtained with 3 nM R1881.
  • Typical tissue-selective androgen receptor modulators of the present invention display weak or no agonist activity in this assay with less than 50% agonist activity at 10 micromolar.
  • This assay assesses the ability of test compounds to antagonize the stimulatory effects of R1881 on the interaction between NTD and CTD of rhAR in a mammalian two-hybrid assay in CV-1 cells as described above.
  • CV-1 cells are treated with test compounds, typically at 10 ⁇ M, 3.3 ⁇ M, 1 ⁇ M, 0.33 ⁇ M, 100 ⁇ M, 33 nM, 10 nM, 3.3 nM and 1 nM final concentrations.
  • test compounds typically at 10 ⁇ M, 3.3 ⁇ M, 1 ⁇ M, 0.33 ⁇ M, 100 ⁇ M, 33 nM, 10 nM, 3.3 nM and 1 nM final concentrations.
  • an AR agonist methyltrienolone R1881
  • luciferase activity is measured using LUC-Screen system (TROPIX) following the protocol recommended by the manufacturer.
  • the ability of test compounds to antagonize the action of R1881 is calculated as the relative luminescence compared to the value with 0.3 nM R1881 alone.
  • SARM compounds of the present invention typically displayed antagonist activity in the present assay with IC 50 values less than 1 micromolar.
  • TAAAR Trans-Activation Modulation of Androgen Receptor
  • This assay assesses the ability of test compounds to control transcription from the MMTV-LUC reporter gene in MDA-MB-453 cells, a human breast cancer cell line that naturally expresses the human AR.
  • the assay measures induction of a modified MMTV LTR/promoter linked to the LUC reporter gene.
  • 20,000 to 30,000 cells/well are plated in a white, clear-bottom 96-well plate in “Exponential Growth Medium” which consists of phenol red-free RPMI 1640 containing 10% FBS, 4 mM L-glutamine, 20 mM HE PES, 10 ug/mL human insulin, and 20 ug/mL gentamicin. Incubator conditions are 37° C. and 5% CO 2 . The transfection is done in batch mode. The cells are trypsinized and counted to the right cell number in the proper amount of fresh media, and then gently mixed with the Fugene/DNA cocktail mix and plated onto the 96-well plate.
  • “Exponential Growth Medium” which consists of phenol red-free RPMI 1640 containing 10% FBS, 4 mM L-glutamine, 20 mM HE PES, 10 ug/mL human insulin, and 20 ug/mL gentamicin. Incubator conditions are 37° C. and
  • the transfection cocktail consists of serum-free Optimem, Fugene6 reagent and DNA. The manufacturer's (Roche Biochemical) protocol for cocktail setup is followed. The lipid ( ⁇ l) to DNA ( ⁇ g) ratio is approximately 3:2 and the incubation time is 20 min at room temperature.
  • the cells are treated with test compounds such that the final DMSO (vehicle) concentration is ⁇ 3%. The cells are exposed to the test compounds for 48 hrs. After 48 hrs, the cells are lysed by a Promega cell culture lysis buffer for 30-60 min and then the luciferase activity in the extracts is assayed in the 96-well format luminometer.
  • Activity of test compounds is calculated as the E max relative to the activity obtained with 100 nM R1881.
  • Rats are orchiectomized (ORX). Each rat is weighed, then anesthetized by isoflurane gas that is maintained to effect. A 1.5 cm anteroposterior incision is made in the scrotum. The right testicle is exteriorized. The spermatic artery and vas deferens are ligated with 4.0 silk 0.5 cm proximal to the testicle. The testicle is freed by one cut of a small surgical scissors distal to the ligation site. The tissue stump is returned to the scrotum. The same is repeated for the left testicle. When both stumps are returned to the scrotum, the scrotum and overlying skin are sutured closed with 4.0 silk. For Sham-ORX, all procedures excepting ligation and scissors cutting are completed. The rats fully recover consciousness and full mobility within 10-15 minutes.
  • test compound is administered subcutaneously or orally to the rat immediately after the surgical incision is sutured. Treatment continues for an additional six consecutive days.
  • the rat is first weighed, then anesthetized in a CO 2 chamber until near death. Approximately 5 ml whole blood is obtained by cardiac puncture. The rat is then examined for certain signs of death and completeness of ORX. Next, the ventral portion of the prostate gland is located and blunt dissected free in a highly stylized fashion. The ventral prostate is blotted dry for 3-5 seconds and then weighed (VPW). Finally, the seminal vesicle is located and dissected free. The ventral seminal vesicle is blotted dry for 3-5 seconds and then weighed (SVWT).
  • Primary data for this assay are the weights of the ventral prostate and seminal vesicle. Secondary data include serum LH (luteinizing hormone) and FSH (follicle stimulating hormone), and possible serum markers of bone formation and virilization. Data are analyzed by ANOVA plus Fisher PLSD post-hoc test to identify intergroup differences. The extent to which test compounds inhibit ORX-induced loss of VPW and SVWT is assessed.
  • mice Female Sprague-Dawley rats aged 7-10 months are used in treatment mode to simulate adult human females.
  • the rats have been ovariectomized (OVX) 75-180 days previously, to cause bone loss and simulate estrogen deficient, osteopenic adult human females.
  • Pre-treatment with a low dose of a powerful anti-resorptive, alendronate (0.0028mpk SC, 2 ⁇ /wk) is begun on Day 0.
  • treatment with test compound is started.
  • Test compound treatment occurs on Days 15-31 with necropsy on Day 32.
  • the goal is to measure the extent to which androgen-like compounds increase the amount of bone formation, shown by increased fluorochrome labeling, at the periosteal surface.
  • the rat is first weighed, then anesthetized in a CO 2 chamber until near death. Approximately 5 mL whole blood is obtained by cardiac puncture. The rat is then examined for certain signs of death and completeness of OVX. First, the uterus is located, blunt dissected free in a highly stylized fashion, blotted dry for 3-5 seconds and then weighed (UW). The uterus is placed in 10% neutral-buffered formalin. Next, the right leg is disarticulated at the hip. The femur and tibia are separated at the knee, substantially defleshed, and then placed in 70% ethanol.
  • Three cross-sections of 85 ⁇ m thickness are prepared and mounted on glass slides. One section from each rat that approximates the midpoint of the bone is selected and blind-coded. The periosteal surface of each section is assessed for total periosteal surface, single fluorochrome label, double fluorochrome label, and interlabel distance.
  • Primary data for this assay are the percentage of periosteal surface bearing double label and the mineral apposition rate (interlabel distance( ⁇ m)/10d), semi-independent markers of bone formation. Secondary data include uterus weight and histologic features. Tertiary endpoints may include serum markers of bone formation and virilization. Data are analyzed by ANOVA plus Fisher PLSD post-hoc test to identify intergroup differences. The extent to which test compounds increase bone formation endpoint are assessed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
US10/512,800 2002-04-30 2003-04-25 4-azasteroid derivatives as androgen receptor modulators Abandoned US20050131005A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/512,800 US20050131005A1 (en) 2002-04-30 2003-04-25 4-azasteroid derivatives as androgen receptor modulators
US11/504,325 US7625919B2 (en) 2002-04-30 2006-08-14 4-azasteroid derivatives as androgen receptor modulators

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37677902P 2002-04-30 2002-04-30
US10/512,800 US20050131005A1 (en) 2002-04-30 2003-04-25 4-azasteroid derivatives as androgen receptor modulators
PCT/US2003/013120 WO2003092588A2 (fr) 2002-04-30 2003-04-25 Derives de 4-azasteroide utilises comme modulateurs du recepteur de l'androgene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/504,325 Continuation US7625919B2 (en) 2002-04-30 2006-08-14 4-azasteroid derivatives as androgen receptor modulators

Publications (1)

Publication Number Publication Date
US20050131005A1 true US20050131005A1 (en) 2005-06-16

Family

ID=29401402

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/512,800 Abandoned US20050131005A1 (en) 2002-04-30 2003-04-25 4-azasteroid derivatives as androgen receptor modulators
US11/504,325 Expired - Fee Related US7625919B2 (en) 2002-04-30 2006-08-14 4-azasteroid derivatives as androgen receptor modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/504,325 Expired - Fee Related US7625919B2 (en) 2002-04-30 2006-08-14 4-azasteroid derivatives as androgen receptor modulators

Country Status (6)

Country Link
US (2) US20050131005A1 (fr)
EP (1) EP1501512A4 (fr)
JP (1) JP4516839B2 (fr)
AU (1) AU2003223754B2 (fr)
CA (1) CA2484173A1 (fr)
WO (1) WO2003092588A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134173A2 (fr) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Reduction et derivation selectives de proteines conçues par le genie genetique comprenant au moins une cysteine non native
WO2007006808A1 (fr) 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Cellules inactivees proteiques de cellules hotes pour la production de proteines therapeutiques
EP2275432A1 (fr) 2003-12-01 2011-01-19 Novo Nordisk Health Care AG Nanofiltration des solutions du facteur VII pour enlever des virus
EP2298287A2 (fr) 2003-12-19 2011-03-23 Novo Nordisk Health Care AG Compositions stabilisees de polypeptides de facteur VII
EP2316930A1 (fr) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Polypéptides humains du facteur de coagulation VII
EP2360171A1 (fr) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Réduction du contenu en contaminants protéiques de compositions renfermant une protéine d'intérêt dépendante de la vitamine K

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2397176C2 (ru) 2004-01-07 2010-08-20 Эндорешерш, Инк. Стероидные фармацевтические продукты, направленные на спираль 12
WO2005097127A2 (fr) 2004-04-02 2005-10-20 Merck & Co., Inc. Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
US20080125399A1 (en) * 2004-04-08 2008-05-29 Jiabing Wang 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators
CN1950086A (zh) * 2004-04-28 2007-04-18 默克公司 作为雄激素受体调节剂的氟化的4－氮杂甾族化合物
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006024931A2 (fr) * 2004-08-31 2006-03-09 Pfizer Products Inc. Combinaisons therapeutiques comprenant un modulateur selectif du recepteur d'oestrogenes et un modulateur selectif du recepteur d'androgenes
WO2006060108A1 (fr) * 2004-10-29 2006-06-08 Merck & Co., Inc. N-(pyridin-3-yl)-2-phenylbutanamides utilises comme modulateurs du recepteur androgene
WO2006058781A2 (fr) * 2004-12-03 2006-06-08 Proteosys Ag Utilisation de finasteride, dutasteride et de composes associes dans la prevention ou le traitement de troubles neurologiquement associes
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CA2800673A1 (fr) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Modulateur du recepteur oestrogenique et utilisation de ces derniers
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
WO2013090829A1 (fr) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Modulateurs des récepteurs des œstrogènes et ses utilisations
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
SG11202003035SA (en) 2017-10-05 2020-04-29 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
IT1270660B (it) * 1994-10-13 1997-05-07 Poli Ind Chimica Spa Procedimento microbiologico per la preparazione di 3-oxo-4-azasteroidi-17beta-carbossi sostituiti e uso dei prodotti come inibitori dell'enzima 5alfa-riduttasi
JP3824636B2 (ja) * 1995-06-07 2006-09-20 グラクソ、ウェルカム、インコーポレーテッド アンドロステノン
AU5594398A (en) * 1996-12-09 1998-07-03 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275432A1 (fr) 2003-12-01 2011-01-19 Novo Nordisk Health Care AG Nanofiltration des solutions du facteur VII pour enlever des virus
EP2298287A2 (fr) 2003-12-19 2011-03-23 Novo Nordisk Health Care AG Compositions stabilisees de polypeptides de facteur VII
EP2311437A1 (fr) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Compositions stabilisees de polypeptides de facteur VII
EP2360171A1 (fr) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Réduction du contenu en contaminants protéiques de compositions renfermant une protéine d'intérêt dépendante de la vitamine K
WO2006134173A2 (fr) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Reduction et derivation selectives de proteines conçues par le genie genetique comprenant au moins une cysteine non native
WO2007006808A1 (fr) 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Cellules inactivees proteiques de cellules hotes pour la production de proteines therapeutiques
EP2316930A1 (fr) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Polypéptides humains du facteur de coagulation VII

Also Published As

Publication number Publication date
JP2005529897A (ja) 2005-10-06
JP4516839B2 (ja) 2010-08-04
CA2484173A1 (fr) 2003-11-13
AU2003223754B2 (en) 2007-08-16
AU2003223754A1 (en) 2003-11-17
US20060281761A1 (en) 2006-12-14
WO2003092588A2 (fr) 2003-11-13
US7625919B2 (en) 2009-12-01
EP1501512A2 (fr) 2005-02-02
WO2003092588A3 (fr) 2004-07-15
EP1501512A4 (fr) 2009-11-18

Similar Documents

Publication Publication Date Title
US7625919B2 (en) 4-azasteroid derivatives as androgen receptor modulators
CA2478186C (fr) Derives de 4-azasteroide fluore en tant que modulateur de recepteur androgenique
AU2002330031B2 (en) Androstanes as androgen receptor modulators
EP1581217A1 (fr) Derives de carbonylamino-benzimidazole utilises comme modulateurs du recepteur androgene
AU2002330031A1 (en) Androstanes as androgen receptor modulators
US20060287349A1 (en) 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
US7482357B2 (en) 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US7402577B2 (en) Androstane 17-beta-carboxamides as androgen receptor modulators
AU2002331916A1 (en) Androstane 17-beta-carboxamides as androgen receptor modulators
US7605152B2 (en) 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
US7329750B2 (en) 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators
US20070088028A1 (en) 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators
US7625920B2 (en) Fluorinated 4-azasteroid derivatives as androgen receptor modulators

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION